Frequently Occurring Developmental Defects in Children
1. Saneha Saneha
2. Uddin Md Zishan
3. Ansari Talib
4. Verma Subhash Kumar
5. Muktarali kyzy Begimai
(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
2. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
3. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
4. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
5. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
Abstract
Developmental defects, encompassing congenital anomalies and structural malformations arising during embryonic and fetal development, represent a significant global health burden affecting millions of children worldwide. This review examines the contemporary understanding of frequently occurring developmental defects in children, integrating recent advances in epidemiological surveillance, pathophysiological mechanisms, preventive strategies, and therapeutic interventions. A comprehensive literature search was conducted focusing on publications from 2017 to 2025, with particular emphasis on Global Burden of Disease 2021 data and current international guidelines. The analysis reveals that congenital heart anomalies, neural tube defects, orofacial clefts, congenital musculoskeletal anomalies, and urogenital malformations constitute the predominant categories, with congenital heart anomalies accounting for approximately 22.8% of congenital birth defects and 46.7% of related deaths globally. The global prevalence of congenital birth defects among children aged 0-14 years reached approximately 31.64 million cases in 2021, representing a 6.68% increase since 1990, with the burden disproportionately concentrated in low- and middle-income countries where access to prenatal diagnosis and surgical correction remains limited. Preventive strategies including periconceptional folic acid supplementation, antenatal corticosteroid administration, rubella immunization, and avoidance of teratogenic exposures have demonstrated substantial efficacy, yet implementation gaps persist. Surgical correction, when accessible, has transformed outcomes for many conditions, though lifelong multidisciplinary care is often required. The integration of genomic diagnostics, fetal imaging, and minimally invasive surgical techniques continues to advance the field, while disparities in access to care remain a pressing global health equity concern.
Introduction
The birth of a child represents a moment of profound hope and anticipation, yet for millions of families worldwide, this joy is tempered by the discovery that their newborn carries a developmental defect—a structural or functional anomaly arising during the intricate process of embryonic and fetal development. These conditions, encompassing congenital heart defects, neural tube defects, orofacial clefts, and myriad other malformations, represent not merely medical diagnoses but profound alterations in the trajectory of a child's life and the fabric of family existence. The World Health Organization estimates that congenital anomalies affect approximately one in every thirty-three infants born globally, translating to millions of affected children each year and constituting a leading cause of infant mortality and childhood disability.
The landscape of developmental defects has been transformed over the past half-century by advances in prenatal imaging, genetic diagnostics, surgical techniques, and preventive interventions. Conditions once universally fatal at birth now carry survival rates exceeding 90% in centers with appropriate expertise, while prenatal screening and folic acid supplementation have reduced the incidence of neural tube defects by more than half in regions with robust public health infrastructure. Yet these advances remain unevenly distributed, with the burden of developmental defects falling disproportionately upon low- and middle-income countries where access to diagnostic and therapeutic resources is limited. The Global Burden of Disease 2021 study documented approximately 31.64 million children worldwide affected by congenital birth defects, with congenital heart anomalies, musculoskeletal anomalies, and urogenital anomalies accounting for the largest proportions of disease burden.
The pathogenesis of developmental defects is multifactorial, arising from complex interactions between genetic predisposition and environmental exposures during critical periods of organogenesis. Chromosomal abnormalities, single-gene mutations, and polygenic inheritance patterns contribute to susceptibility, while maternal factors including nutritional deficiencies, infections, teratogenic exposures, and chronic diseases modify risk. The timing of insults during gestation critically determines the nature and severity of resulting defects, with major organogenesis occurring during the first eight weeks of embryonic development representing the period of greatest vulnerability.
This review aims to provide a comprehensive examination of frequently occurring developmental defects in children, encompassing the epidemiological burden, pathophysiological mechanisms, clinical manifestations, preventive strategies, and contemporary management approaches. Through this synthesis, we seek to illuminate both the remarkable progress achieved in understanding and treating these conditions and the persistent challenges that demand continued innovation and global health equity initiatives.
Methods
A comprehensive literature search was conducted to identify relevant publications addressing developmental defects in children. The search encompassed databases including PubMed, MEDLINE, and the Cochrane Library, with primary focus on literature published between January 2017 and October 2025 to ensure inclusion of contemporary guidelines and emerging evidence. Search terms incorporated "congenital anomalies," "developmental defects," "congenital heart defects," "neural tube defects," "orofacial clefts," "congenital musculoskeletal anomalies," "urogenital anomalies," "epidemiology," "prevention," "folic acid," "prenatal diagnosis," and "surgical management."
Inclusion criteria prioritized original research articles, systematic reviews, meta-analyses, clinical practice guidelines, and epidemiological surveillance reports specifically addressing developmental defects in pediatric populations. The methodological framework emphasized evidence-based guidelines including the World Health Organization's congenital anomalies surveillance manual, the Global Burden of Disease 2021 study findings, and statements from international professional societies including the American Heart Association, the International Society for Pediatric and Adolescent Diabetes, and the International Clearinghouse for Birth Defects Surveillance and Research. Particular attention was directed toward studies characterizing disease burden, evaluating preventive interventions, and examining long-term outcomes of affected children.
The analysis synthesized data from multiple study designs, acknowledging the inherent challenges of congenital anomaly research including the heterogeneity of diagnostic criteria across regions, the variability in access to diagnostic resources, and the ethical complexities of research involving vulnerable pediatric populations. Where evidence was limited or conflicting, findings were interpreted with appropriate caveats regarding the certainty of conclusions.
Results
Epidemiology and Global Burden
Developmental defects represent a substantial and growing global health burden, with the Global Burden of Disease 2021 study documenting approximately 31.64 million children aged 0-14 years affected by congenital birth defects worldwide. This figure represents a 6.68% increase since 1990, driven primarily by population growth and improved survival rather than increased incidence rates. The distribution of specific defect categories reveals that congenital musculoskeletal and limb anomalies account for 27.8% of cases, congenital heart anomalies for 22.8%, and urogenital congenital anomalies for 13.9%. However, the mortality burden differs substantially from the prevalence distribution, with congenital heart anomalies responsible for 46.7% of congenital birth defect-related deaths globally, followed by other congenital anomalies and neural tube defects.
The geographic distribution of developmental defects demonstrates marked disparities, with the highest prevalence concentrated in low- and middle-income countries, particularly in sub-Saharan Africa and South Asia. India, Nigeria, and China account for the largest absolute numbers of affected children, reflecting both their large birth cohorts and, in some regions, limited access to preventive and therapeutic interventions. The age-standardized incidence rate of birth defects in 2021 was estimated at 5,563.72 per 100,000 population, with approximately 7.2 million new cases diagnosed annually. However, these figures likely substantially underestimate the true burden given the limited surveillance capacity in many high-burden settings and the under-ascertainment of defects that are not immediately apparent at birth.
Temporal trends over the past three decades reveal divergent patterns across defect categories. Neural tube defects, Down syndrome, and orofacial clefts have demonstrated substantial declines in age-standardized incidence rates—35.79%, 28.76%, and 24.79% respectively—attributable to folic acid fortification programs, prenatal screening with elective termination of affected pregnancies, and improved maternal nutrition. Conversely, the incidence of certain other anomalies has remained stable or increased, with Klinefelter syndrome demonstrating a modest 3% increase in age-standardized incidence rate. The mortality burden has declined substantially for most categories, with orofacial clefts demonstrating a remarkable 91.3% reduction in age-standardized death rates, reflecting advances in surgical correction and perioperative care.
Congenital Heart Anomalies
Congenital heart defects represent the most common category of severe developmental defects, affecting approximately 8-12 per 1,000 live births globally and accounting for the largest proportion of defect-related mortality. The spectrum encompasses structural abnormalities of the heart and great vessels including ventricular septal defects, atrial septal defects, tetralogy of Fallot, transposition of the great arteries, and hypoplastic left heart syndrome. The pathogenesis involves complex interactions between genetic factors—including chromosomal abnormalities such as Down syndrome, 22q11 deletion syndrome, and Turner syndrome—and environmental influences including maternal diabetes, rubella infection, and teratogenic exposures.
The clinical manifestations of congenital heart defects vary enormously depending on the specific lesion and its hemodynamic consequences. Critical congenital heart defects, defined as lesions requiring intervention within the first month of life, may present with cyanosis, respiratory distress, poor feeding, lethargy, or shock. Left-to-right shunts such as ventricular septal defects typically present later with symptoms of congestive heart failure including tachypnea, poor feeding, and failure to thrive. Obstructive lesions including aortic stenosis and coarctation of the aorta may present with diminished pulses, differential blood pressure between extremities, or heart failure.
The diagnosis of congenital heart defects increasingly occurs prenatally through fetal echocardiography, which can identify major structural abnormalities from 18-22 weeks of gestation. Postnatal diagnosis relies on clinical examination, pulse oximetry screening, chest radiography, electrocardiography, and echocardiography. The introduction of pulse oximetry screening for critical congenital heart defects has improved early detection, with studies demonstrating that screening identifies cases that might otherwise be missed before discharge.
Surgical correction has transformed the prognosis for most congenital heart defects, with survival rates exceeding 90% for many lesions in centers with appropriate expertise. The timing of intervention varies by lesion, with some defects requiring neonatal surgery while others can be managed with elective repair in infancy or childhood. Transcatheter techniques including device closure of septal defects and balloon valvuloplasty have expanded treatment options for selected patients. However, even after successful repair, many patients require lifelong follow-up for residual lesions, arrhythmias, and the long-term consequences of altered hemodynamics.
Neural Tube Defects
Neural tube defects, resulting from failure of neural tube closure during the fourth week of embryonic development, represent a significant category of developmental defects with substantial morbidity and mortality. The spectrum includes anencephaly, encephalocele, and spina bifida, with myelomeningocele being the most common form compatible with survival. The global incidence of neural tube defects has declined substantially in regions with folic acid fortification programs, with age-standardized incidence rates decreasing by 35.79% between 1990 and 2021. However, these defects remain common in many low- and middle-income countries where fortification has not been implemented and periconceptional folic acid supplementation is not widely practiced.
The pathogenesis of neural tube defects involves complex interactions between genetic susceptibility and environmental factors. Maternal folate deficiency represents the most important modifiable risk factor, with periconceptional folic acid supplementation reducing the risk of neural tube defects by 50-70%. Other risk factors include maternal diabetes, obesity, hyperthermia, certain medications including valproic acid and carbamazepine, and genetic polymorphisms affecting folate metabolism. The recurrence risk after one affected pregnancy is approximately 3-5%, increasing to 10-15% after two affected pregnancies.
The clinical manifestations of neural tube defects depend on the level and extent of the lesion. Anencephaly, characterized by absence of the cranial vault and cerebral hemispheres, is uniformly fatal. Encephalocele involves herniation of brain tissue through a skull defect, with outcomes varying by the amount of neural tissue involved and associated anomalies. Spina bifida, particularly myelomeningocele, presents with motor and sensory deficits below the level of the lesion, bladder and bowel dysfunction, and orthopedic deformities including clubfoot and scoliosis. Hydrocephalus requiring ventriculoperitoneal shunting develops in the majority of patients with myelomeningocele.
The management of neural tube defects has been transformed by advances in surgical technique and multidisciplinary care. Prenatal diagnosis through maternal serum alpha-fetoprotein screening and detailed ultrasound examination enables counseling and planning for delivery at a center with appropriate expertise. Fetal surgery for myelomeningocele closure, pioneered at select centers, has demonstrated improved neurological outcomes compared to postnatal closure in the landmark Management of Myelomeningocele Study (MOMS), though with increased risks of preterm delivery and maternal complications. Postnatal management involves closure of the defect, shunting for hydrocephalus, and lifelong multidisciplinary care addressing neurological, urological, orthopedic, and psychosocial needs.
Orofacial Clefts
Orofacial clefts, encompassing cleft lip with or without cleft palate and isolated cleft palate, represent among the most common craniofacial malformations, affecting approximately 1-2 per 1,000 live births globally. The incidence demonstrates substantial geographic and ethnic variation, with highest rates reported in Native American and Asian populations and lowest rates in African populations. The pathogenesis involves failure of fusion of the facial processes during the sixth to twelfth weeks of embryonic development, resulting from complex interactions between genetic susceptibility and environmental factors.
The clinical manifestations of orofacial clefts extend far beyond the visible deformity, encompassing feeding difficulties, speech impairment, dental anomalies, hearing loss from middle ear effusions, and psychosocial challenges. Cleft lip with or without cleft palate typically presents at birth with the characteristic facial deformity, while isolated cleft palate may be less immediately apparent but can severely impact feeding and speech development. The severity ranges from incomplete clefts affecting only the lip to complete bilateral clefts involving the lip, alveolus, and palate.
The management of orofacial clefts requires a coordinated multidisciplinary approach involving plastic surgery, otolaryngology, speech therapy, orthodontics, audiology, and psychology. Primary surgical repair of the lip typically occurs at 3-6 months of age, with palate repair at 9-18 months to optimize speech development while minimizing effects on facial growth. Secondary procedures including alveolar bone grafting, rhinoplasty, and orthognathic surgery may be required during childhood and adolescence. The remarkable 91.3% decline in age-standardized death rates from orofacial clefts over the past three decades reflects the success of surgical correction and comprehensive care.
Congenital Musculoskeletal Anomalies
Congenital musculoskeletal anomalies encompass a diverse group of developmental defects affecting the limbs, spine, and axial skeleton. These conditions, accounting for 27.8% of congenital birth defects globally, range from relatively minor anomalies such as polydactyly to severe limb reduction defects and complex spinal deformities. The pathogenesis involves disruptions in the complex processes of limb bud formation, patterning, and differentiation during embryonic development, with genetic factors, vascular disruptions, and environmental exposures all contributing.
Congenital talipes equinovarus, commonly known as clubfoot, represents one of the most frequent musculoskeletal anomalies, affecting approximately 1-2 per 1,000 live births. The condition presents at birth with the characteristic inward and downward turning of the foot, resulting from abnormalities in the bones, muscles, and tendons of the lower leg. The Ponseti method, involving serial casting and percutaneous Achilles tenotomy followed by bracing, has revolutionized treatment, achieving correction in over 95% of cases without the need for extensive surgery when initiated early.
Developmental dysplasia of the hip encompasses a spectrum of abnormalities from mild acetabular dysplasia to complete dislocation of the femoral head. Risk factors include breech presentation, female sex, family history, and certain cultural practices including swaddling with the hips extended. Early diagnosis through clinical examination including the Ortolani and Barlow maneuvers and selective ultrasound screening enables treatment with Pavlik harness or other orthotic devices, with surgical intervention reserved for cases diagnosed late or failing conservative management.
Congenital limb reduction defects, including amelia, phocomelia, and transverse deficiencies, result from vascular disruptions, genetic mutations, or teratogenic exposures. The thalidomide tragedy of the 1960s demonstrated the devastating potential of teratogenic exposures to cause limb reduction defects, while more recent associations include maternal diabetes and certain vascular events. Management involves prosthetic fitting, surgical reconstruction, and rehabilitation to maximize functional independence.
Urogenital Anomalies
Congenital urogenital anomalies, affecting approximately 13.9% of children with birth defects, encompass malformations of the kidneys, ureters, bladder, urethra, and external genitalia. These conditions range from relatively common and often asymptomatic anomalies such as vesicoureteral reflux to severe life-threatening conditions including bilateral renal agenesis and bladder exstrophy. The pathogenesis involves disruptions in the complex processes of urogenital development, which are intimately linked with the development of the reproductive system.
Hypospadias, characterized by abnormal placement of the urethral opening on the ventral surface of the penis, represents one of the most common urogenital anomalies, affecting approximately 1 in 250 male births. The severity varies from mild distal forms to severe proximal cases with associated chordee and bifid scrotum. Surgical correction, typically performed between 6 and 18 months of age, aims to create a normal-appearing penis with the urethral opening at the tip, enabling standing urination and normal sexual function.
Congenital adrenal hyperplasia, most commonly caused by 21-hydroxylase deficiency, represents a life-threatening condition that can cause ambiguous genitalia in females and adrenal crisis in both sexes. Newborn screening programs have been implemented in many countries to enable early diagnosis and treatment with glucocorticoid and mineralocorticoid replacement, preventing life-threatening adrenal crises and reducing the need for sex assignment surgery in infancy.
Posterior urethral valves, occurring exclusively in males, represent the most common cause of bladder outlet obstruction in children. The condition presents with varying severity from prenatal hydronephrosis detected on ultrasound to renal failure and pulmonary hypoplasia in severe cases. Endoscopic valve ablation represents the primary treatment, with prenatal interventions including vesicoamniotic shunting considered for severe cases with oligohydramnios.
Prevention and Public Health Strategies
The prevention of developmental defects represents a critical public health priority, with substantial evidence supporting the efficacy of several interventions. Periconceptional folic acid supplementation, typically 400-800 micrograms daily beginning before conception and continuing through the first trimester, reduces the risk of neural tube defects by 50-70%. Food fortification programs, mandatory in over 80 countries, have demonstrated population-level reductions in neural tube defect incidence, though implementation remains incomplete in many high-burden regions.
Rubella immunization represents another highly effective preventive strategy, as congenital rubella syndrome can cause cardiac defects, cataracts, sensorineural deafness, and developmental delay. Universal childhood immunization with measles-mumps-rubella vaccine, with high coverage rates, has virtually eliminated congenital rubella syndrome in many developed countries, though the condition persists in regions with suboptimal vaccine coverage.
The management of maternal diabetes represents an important preventive opportunity, as pregestational diabetes substantially increases the risk of congenital heart defects, neural tube defects, and caudal regression syndrome. Optimal glycemic control before conception and during early pregnancy reduces these risks, though complete normalization may not eliminate the increased risk associated with diabetes.
Avoidance of teratogenic exposures including alcohol, tobacco, certain medications, and environmental toxins represents an important preventive strategy. Preconception counseling for women with chronic medical conditions or taking potentially teratogenic medications enables optimization of treatment before pregnancy. The use of isotretinoin for acne, valproic acid for epilepsy, and warfarin for thromboembolic disease requires particular attention given their well-documented teratogenic potential.
Diagnosis and Management
The diagnosis of developmental defects increasingly occurs prenatally through a combination of maternal serum screening, detailed ultrasound examination, and invasive diagnostic testing including amniocentesis and chorionic villus sampling. First-trimester screening combining nuchal translucency measurement with maternal serum markers enables early risk assessment for chromosomal abnormalities, while second-trimester anatomy scans can identify major structural abnormalities. The development of non-invasive prenatal testing using cell-free fetal DNA has revolutionized screening for chromosomal abnormalities, offering high sensitivity and specificity without the risks of invasive procedures.
Fetal imaging has advanced substantially, with three-dimensional ultrasound, fetal magnetic resonance imaging, and fetal echocardiography enabling detailed assessment of structural anomalies. These technologies facilitate accurate diagnosis, counseling regarding prognosis, and planning for delivery at a center with appropriate expertise. Fetal interventions, including surgery for myelomeningocele, balloon valvuloplasty for critical aortic stenosis, and laser ablation for twin-twin transfusion syndrome, have expanded treatment options for selected conditions, though they remain available only at specialized centers.
Postnatal management of developmental defects requires a multidisciplinary approach involving pediatric specialists, surgeons, therapists, and support services. The timing of surgical intervention varies by condition, with some defects requiring emergency neonatal surgery while others can be managed with elective repair. Advances in surgical techniques including minimally invasive approaches, tissue engineering, and regenerative medicine continue to expand treatment possibilities.
The long-term care of children with developmental defects extends beyond surgical correction to address functional limitations, psychosocial adjustment, and quality of life. Transition programs to adult care, recognition of neurodevelopmental sequelae, and support for families are essential components of comprehensive care. The economic burden of developmental defects, including direct medical costs and indirect costs related to lost productivity and caregiving, is substantial and represents an important consideration for health policy.
Discussion
The landscape of developmental defects in children has been transformed by advances in prevention, diagnosis, and treatment, yet substantial challenges persist. The Global Burden of Disease 2021 data reveal divergent trends across defect categories, with some conditions demonstrating remarkable declines in incidence and mortality while others remain stubbornly prevalent. The success of folic acid fortification in reducing neural tube defects and of surgical correction in reducing mortality from orofacial clefts demonstrates the potential for effective interventions to substantially reduce the burden of developmental defects. However, the persistence of high rates in many low- and middle-income countries underscores the critical importance of equitable access to preventive and therapeutic resources.
The pathogenesis of developmental defects involves complex interactions between genetic susceptibility and environmental exposures, with the timing of insults during gestation critically determining outcomes. Advances in genomic technologies including chromosomal microarray analysis, whole exome sequencing, and whole genome sequencing have substantially improved the diagnostic yield for children with developmental defects, enabling more accurate prognostication, recurrence risk counseling, and in some cases, targeted therapies. The integration of genomic information with detailed phenotyping through initiatives such as the Deciphering Developmental Disorders study has advanced understanding of the genetic architecture of these conditions.
The ethical dimensions of developmental defects warrant careful consideration. Prenatal diagnosis raises complex questions about reproductive choice, disability rights, and the value placed on lives affected by congenital anomalies. The availability of prenatal screening and elective termination of affected pregnancies has contributed to declining incidence rates for some conditions, yet this approach is not universally accepted and may not be accessible or acceptable in all cultural contexts. The perspectives of individuals living with developmental defects and their families must inform policy and practice.
The disparities in access to care for developmental defects represent a pressing global health equity concern. While survival rates for conditions such as congenital heart defects exceed 90% in high-income countries, mortality remains substantially higher in low- and middle-income countries where access to surgical correction is limited. The concentration of specialized surgical expertise in high-income countries leaves many children without access to life-saving interventions. Initiatives to build capacity in low- and middle-income countries, including training programs, telemedicine, and international partnerships, are essential to address these disparities.
Future directions in the field of developmental defects include the continued refinement of genomic diagnostics, the development of novel preventive strategies, and the advancement of therapeutic interventions including regenerative medicine and gene therapy. The application of artificial intelligence to imaging analysis may improve prenatal detection rates, while advances in fetal surgery may expand the range of conditions amenable to prenatal intervention. The integration of patient-reported outcomes and quality of life measures into research and clinical practice will ensure that interventions truly benefit affected children and their families.
Conclusion
Developmental defects in children represent a significant and persistent global health burden, with congenital heart anomalies, neural tube defects, orofacial clefts, congenital musculoskeletal anomalies, and urogenital malformations constituting the predominant categories. While advances in prevention, prenatal diagnosis, and surgical treatment have substantially improved outcomes for many conditions, disparities in access to care remain a pressing concern. The integration of genomic diagnostics, fetal imaging, and multidisciplinary care continues to advance the field, offering hope for further improvements in the lives of affected children. Continued investment in prevention, early detection, and equitable access to treatment is essential to reducing the global burden of developmental defects and ensuring that all children, regardless of where they are born, have the opportunity to reach their full potential.
References
Li Y, He C, Yu H, Wu D, Liu L, Zhang X. Global, regional, and national epidemiology of congenital birth defects in children from 1990 to 2021: a cross-sectional study. J Glob Health. 2025;15:04012.
Global, regional, and national burden and trends of congenital birth defects from 1990 to 2021: epidemiological trends, health inequalities, and COVID-19 impact. Transl Pediatr. 2025;14(2):849-863.
GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories, 1990-2021. Lancet. 2024;403:2133-2161.
GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories, 1990-2021. Lancet. 2024;403:2100-2132.
Almli LM, Ely DM, Ailes EC, Abouk R, Grosse SD, Isenburg JL, et al. Infant mortality attributable to birth defects - United States, 2003-2017. MMWR Morb Mortal Wkly Rep. 2020;69:25-29.
Li XY, Hou MJ, Kong XM, Lv JJ, Yang CH, Li DT, et al. The congenital birth defects burden in children younger than 14 years of age, 1990-2019: an age-period-cohort analysis of the global burden of disease study. J Glob Health. 2024;14:04012.
Martínez-García M, Gutiérrez-Esparza GO, Roblero-Godinez JC, Marín-Pérez DV, Montes-Ruiz CL, Vallejo M, et al. Cardiovascular risk factors and social development index. Front Cardiovasc Med. 2021;8:631747.
Burden of urogenital congenital anomalies: findings from the global burden of disease study 2021. Front Pediatr. 2025;13:1584280.
World Health Organization. Congenital anomalies. Fact sheet. Geneva: WHO; 2024.
World Health Organization. Congenital anomalies surveillance: a manual for programme managers. Geneva: WHO; 2014.
Mersereau P, Kilker K, Carter H, Fassett E, Williams J, Flores A, Prue C, Williams L, Mai C. Spina bifida and anencephaly before and after folic acid mandate - United States, 1995-1996 and 1999-2000. MMWR Morb Mortal Wkly Rep. 2004;53(17):362-365.
Adzick NS, Thom EA, Spong CY, Brock JW 3rd, Burrows PK, Johnson MP, et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med. 2011;364(11):993-1004.
Ponseti IV. Congenital clubfoot: fundamentals of treatment. Oxford: Oxford University Press; 1996.
Graf R. Fundamentals of sonographic diagnosis of infant hip dysplasia. J Pediatr Orthop. 1984;4(6):735-740.
American Academy of Pediatrics, Section on Cardiology and Cardiac Surgery. Recommendations for physical activity in children with congenital heart disease. Pediatrics. 2006;118(4):1824-1835.
Mitchell LE, Beaty TH, Laird E. Evaluation of recurrence risk in a family with isolated cleft lip and palate. Am J Med Genet. 1991;41(1):76-80.
Centers for Disease Control and Prevention. Racial/ethnic differences in the birth prevalence of spina bifida - United States, 1995-2005. MMWR Morb Mortal Wkly Rep. 2009;58(48):1409-1413.
International Clearinghouse for Birth Defects Surveillance and Research. Annual Report 2022. Rome: ICBDSR; 2023.
Botto LD, Moore CA, Khoury MJ, Erickson JD. Neural-tube defects. N Engl J Med. 1999;341(20):1509-1519.
Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39(12):1890-1900.